

ETERNIabrio

Everolimus Eluting
Coronary Stent System

Stent Length(mm)

Diameter (mm)	8	12	16	20	24	28	32	36	40	44	48
2.25	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
2.50	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
2.75	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
3.00	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
3.50	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
4.00	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

Stent Specifications

Design	Open Cell Design
Material	L605 Cobalt Chromium
Strut Thickness	65 µm
Strut Width	80 µm
Foreshorteing	Nearly Zero
Recoil	<4 %
Crossing profile	1 mm
Guiding Catheter	5 Fr Compatible
Radial Strength	Excellent
Flexibility	Excellent


Manufactured by



Innovation Healthcare Private Limited
Plot No. 105, Solitaire Industrial Park, Village Dehmikalan,
The. Sanganer, Jaipur – 303007, Rajasthan (India)
Telephone No.: +91-120-4193839,
FAX: +91-120-4193839.
Email: qa@innovation.in **Website:** www.innovation.in
Manufacturing License No.: MFG/MD/2022/000680



* 68 micron with drug and polymer coating



Everolimus Eluting
Coronary Stent System

ETERNIabrio

Everolimus Eluting
Coronary Stent System

ETERNIAbrio

“Unique stent design together with proven efficacy of Everolimus drug & Bioresorbable polymers resulted into ETERNIAbrio with excellent safety & efficacy profile”

Mid cells allow side branch access & homogenous stress distribution upon expansion

Thinner balloon provides low crossing profile hence increases deliverability of stent

Position of Connector ensures zero foreshortening

Established Everolimus efficacy

Best-in-Class Deliverability

Superior Flexibility

Proven blend of everolimus & Bioresorbable Polymers

ETERNIA brio


Enhanced Outcomes Attributed by Clinically Proven Everolimus Drug

Everolimus drug being more lipophilic than other limus family drug penetrates rapidly at the target lesion and provides rapid cell inhibitory action. Everolimus stents are well proven to show less restenosis, stent thrombosis and periprocedural myocardial infarction compared to earlier generation of Drug Eluting Stents

Redefining Deliverability

- Enhanced stent delivery system brings exceptional performance in complex lesions & challenging anatomy.
- Unique shaft specifically engineered to enhance overall pushability and trackability. Unique coating technology to deliver ultimate speed and reliability.
- Higher tensile strength polymer tubing to improve kink resistance & retain flexible performance

% Cumulative Drug Release



Drug Release Kinetics

ETERNIAbrio has proven drug release kinetics. Initial burst of Everolimus followed by sustained release up to 40 days. Bioresorbable Polymers completely degrades by hydrolysis & enzymatic degradation which is eventually excreted from the body in form of CO₂ and H₂O.